AstraZeneca's Imfinzi Cements Market Position In Lung Cancer Segment With UK NICE Okay
But because of the remaining uncertainty in the clinical evidence for this "potentially curative treatment," – Imfinzi for Stage III NSCLC – UK reimbursement will come from the Cancer Drugs Fund until more data accrues from the PACIFIC study, due to report in 2021.
You may also be interested in...
Tagrisso, Lynparza and Imfinzi are enjoying stellar sales growth which is unlikely to slow down any time soon.
Full PACIFIC data show strong overall survival benefit in all comers, though not in a post hoc analysis of those with low PD-L1 expression, about 20% of the population.
Imfinzi will be the fourth PD-1/L1 inhibitor approved for lung cancer in Europe, but AstraZeneca could carve out a niche by being indicated for sequential use following chemoradiation.